|MDACC Study No:||2010-0727 (clinicaltrials.gov NCT No: NCT01303796)|
|Title:||A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia|
|Principal Investigator:||Hagop Kantarjian|
|Treatment Agent:||Cytarabine; Decitabine; Sapacitabine|
|Study Description:||The goal of this clinical research study is to compare the ability of |
decitabine given alone versus the combination of sapacitabine and decitabine to
control AML. The safety of the drug combination will also be studied.